AUTH/3779/6/23 & AUTH/3780/6/23: Ex-employee complaint about alliance promotional material approval process (BI/Lilly) – No breach

📅 2023 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numbersAUTH/3779/6/23 (Boehringer Ingelheim) and AUTH/3780/6/23 (Eli Lilly)
PartiesEx-employee (anonymous, non-contactable) v Boehringer Ingelheim and Eli Lilly
IssueConcerns about the alliance promotional material approval process (PMAP): SOP accessibility/version control; training accessibility/documentation; alleged “agreements outside PMAP”
Applicable Code2021
Clauses consideredClause 5.1; Clause 9.1
OutcomeNo breach of Clause 5.1; No breach of Clause 9.1 (both cases)
Complaint received19 June 2023
Case completed21 August 2024
AppealNo appeal
SanctionsNone stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
📋

What happened

  • An anonymous, non-contactable complainant (described as a former employee) raised concerns about the promotional material approval process (PMAP) used within the Boehringer Ingelheim (BI) and Eli Lilly alliance.
  • Allegations focused on: (1) accessibility of the most up-to-date approved SOP, (2) accessibility and documentation of training (including onboarding and refreshers), and (3) alleged “agreements outside of the PMAP between individual job originators and certifiers”.
  • BI said the PMAP SOP was formally approved by both companies’ Country Managing Directors, stored in BI’s Quality Management System (Vault Quality Docs) and linked via BI’s internal Legal & Compliance SharePoint; Lilly staff accessed the effective SOP via an Alliance MS Teams channel/folder.
  • BI acknowledged that a working draft Word version of the SOP had at times been housed in the same MS Teams folder and said it removed the draft to avoid confusion.
  • Both companies said training was provided and recorded (BI via Learning One Source; Lilly provided training slides and training records for relevant staff/contractors).
  • The Panel noted the complainant provided no supporting evidence (eg, the alleged tracked-changes SOP file, examples of “agreements outside PMAP”, or evidence of training inaccessibility).
⚖️

Outcome

  • No breach of Clause 5.1 in both cases.
  • No breach of Clause 9.1 in both cases.
  • The Panel considered the complainant had not established the allegations on the balance of probabilities.
  • The Panel queried what procedures ensured Lilly always had the most up-to-date SOP in MS Teams after BI QMS updates; Lilly made no submission on that point, but the Panel still ruled no breach based on the information before it.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Charter Member — Until 31 March

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export. £1,999/year £2,499

Get Charter Access →

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free